← Product Code [LON](/productcode/LON) · K060088 # MICROSCAN SYNERGIES PLUS GRAM POSITIVE MIC/COMBO PANELS - AMPICILLIN (K060088) _Dade Behring, Inc. · LON · Feb 3, 2006 · Microbiology · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K060088 ## Device Facts - **Applicant:** Dade Behring, Inc. - **Product Code:** [LON](/productcode/LON.md) - **Decision Date:** Feb 3, 2006 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.1645 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use The MicroScan® Synergies plus™ Gram-Positive MIC/Combo Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-positive staphylococci and enterococci. After inoculation, panels are incubated for 4.5 - 18 hours at 35°C +/- 1°C, in a WalkAway® SI, or equivalent, and read by the MicroScan® Instrumentation. Additionally, the panels may be incubated in a non-CO2 incubator and the Antimicrobial Susceptibility Testing (AST) portions can be read visually, according to the Package Insert. This particular submission is for the addition of the antimicrobial Ampicillin, at concentrations of 0.12 to 64 ug/ml for the Long Dilution Sequence and 2 - 8 µg/ml for the Breakpoint Dilution Sequence, to the test panel. ## Device Story MicroScan® Synergies plus™ Gram-Positive MIC/Combo Panels are miniaturized broth dilution susceptibility tests. Panels contain dehydrated antimicrobial agents (including Ampicillin) in concentrations bridging clinical interest. Workflow: inoculation of panels with standardized organism suspension; rehydration with Synergies plus™ Pos Broth; incubation in WalkAway® SI System (or equivalent) for 4.5–18 hours. Device uses Rapid Fluorogenic Identification and Dried Overnight AST technologies. Output: Minimum Inhibitory Concentration (MIC) determined by lowest antimicrobial concentration showing growth inhibition. Used in clinical laboratories by trained personnel. Results assist healthcare providers in selecting appropriate antimicrobial therapy for gram-positive infections. ## Clinical Evidence Performance evaluated using 306 Enterococci isolates (213 fresh, 75 challenge) across 3 sites. Comparison against CLSI reference broth dilution method. Primary endpoints: Essential Agreement (EA) and Category Agreement (CA). Combined results showed 97.8% EA and 99.7% CA. Very major discrepancy rate was 1/111 (0.9%). Reproducibility study (10 isolates, 3 sites, 3 days) showed >95% reproducibility for all reading methods (early and overnight). Bench testing confirmed performance across reading timeframes (4.5-18 hours). ## Technological Characteristics Miniaturized broth dilution panels; dehydrated antimicrobial agents in water/buffer/broth. Sensing principle: Rapid Fluorogenic Identification and growth inhibition detection. Incubation: 4.5-18 hours at 35°C. Connectivity: WalkAway® SI System or equivalent. Software: Automated reading of MIC via instrument. ## Regulatory Identification A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases. ## Special Controls *Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.” ## Predicate Devices - MicroScan® Synergies plus™ Gram-Negative MIC/Combo Panels - MicroScan® Dried Gram-Positive Panels ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 1 # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: K060088 B. Purpose for Submission: To add Ampicillin to the MicroScan® Synergies plus™ Gram-Positive MIC/Combo Panels C. Measurand: Ampicillin at 0.12-64 µg/mL or 2-8 µg/mL D. Type of Test: Quantitative and Qualitative growth based detection algorithm using optics light detection E. Applicant: Dade Behring Inc, MicroScan® F. Proprietary and Established Names: MicroScan® Synergies plus™ Gram-Positive MIC/Combo Panels G. Regulatory Information: 1. Regulation section: 866.1645 - Fully automated short-term incubation cycle antimicrobial susceptibility system 866.1640 - Antimicrobial Susceptibility Test Powder 2. Classification: Class II 1. Product code: LON – Automated AST system short incubation {1} LRG-Instrument for Auto Reader & Interpretation of Overnight Antimicrobial Susceptibility Systems JWY - Manual Antimicrobial Susceptibility Test Systems LTT – Panels, Test, Susceptibility, Antimicrobial 4. Panel: 83 Microbiology H. Intended Use: 1. Intended use(s): Ampicillin at concentrations of 0.12-64 µg/mL on the MicroScan® Synergies plus™ Gram-Positive MIC/Combo Panel is intended for use with MicroScan® Synergies plus™ Panels read on the WalkAway® -SI System (including upgraded WalkAway® -40 or WalkAway® -96 to meet WalkAway® SI equivalence). MicroScan® panels are designed for use in determining identification to the species level of colonies, grown on solid media, of rapidly growing aerobic and facultative anaerobic gram-positive cocci and Listeria; the panels also provide quantitative and/or qualitative antimicrobial agent susceptibility for Staphylococci and Enterococci. 2. Indication(s) for use: The testing of Ampicillin at concentrations of 0.12-64 µg/mL or 6-8 µg/mL (Breakpoint Dilution Sequence) on the gram-positive test panel for testing Enterococcus spp. at 4.5-18 hours for either an earlier reading or an overnight reading 3. Special conditions for use statement(s): - Turbidity method of inoculum preparation only. - For prescription use only. 4. Special instrument requirements: Not Applicable I. Device Description: Each panel contains two control wells: a negative control well, and a growth control well (contains test medium without antibiotic). Antibiotics are diluted in water, buffer, or minute concentrations of broth to selected concentrations prior to dehydration of the panels. The panel is rehydrated and inoculated at the same time with 0.1 ml of suspension prepared by the turbidity method (inoculum prepared in 0.4% saline with PLURONIC®, then 0.1 ml transferred to 25 ml of inoculum Synergies plus Pos Broth with PLURONIC®) for a final inoculum concentration of 3-7 X 10⁵ CFU/ml. Panels are incubated in a Walk-Away® System and read 2 {2} periodically starting at 4.5 hours until sufficient growth to determine the MIC. Alternately the panels may be incubated at 35° C in a non-CO₂ for 16-24 hours and read by visual observation of growth. J. Substantial Equivalence Information: 1. Predicate device name(s): MicroScan® Dried Gram-Positive and Gram-Negative MIC/Combo Panels 2. Predicate 510(k) number(s): k862140 k020185 3. Comparison with predicate: | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Intended use | MicroScan® panels are designed for use in determining quantitative and/or qualitative antimicrobial agent susceptibility and/or identification to the species level of colonies, grown on solid media, of rapidly growing aerobic and facultative anaerobic organisms | Same | | Specimen | Isolated colonies from culture used | Same | | Inoculum | Inoculum density to 0.5 McFarland standard | Same | | Incubation | <16 hours;16 – 20 hours | Same | | Results | Quantitative with qualitative interpretations | Same | | Technology | Growth based | Same | | Differences | | | | Item | Device | Predicate | | Panels | Dried in water | Dried clindamycin or gentamicin in broth | | Reading | Uses both an early and overnight read algorithm in the same system | Overnight system uses only the overnight reading methods and <16 hour instruments use only the <16 hour read methods. | | Inoculum preparation | Turbidity method of inoculation only. | Inoculum prepared from isolated colonies using either the Turbidity method or Prompt® system | | Instrument | WalkAway® -SI System or equivalent | autoScan® -4 or WalkAway® | | Antibiotic | Ampicillin at 0.12-64 μg/mL and 2-8μg/mL | Different concentrations depending on the antibiotic | {3} 4 K. Standard/Guidance Document Referenced (if applicable): Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA”; Clinical and Laboratory Standards Institute (CLSI) M7 (M100-S16) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard”. L. Test Principle: The WalkAway® SI uses a Colorimetric Optics System consisting of a color wheel/lamp assembly and a Photosensor. There is an initial read at 2.5 hours with a possible final read at 4.5, 5.5, 6.5, 8, 12, 16, or 18 hours (overnight instrument readings, manual readings) depending on the growth rate of the organism being tested. The time of final read is dependent on the growth rate of the organism and the sensitivity of the automatic reader since cell densities below $2 \times 10^{7}$ cells/ml are not detected. M. Performance Characteristics (if/when applicable): 1. Analytical performance: a. Precision/Reproducibility: Reproducibility was demonstrated using 10 isolates tested at 3 sites on 3 separate days in triplicate. The study included the testing on the WalkAway® SI read at <16 hours, WalkAway® 16-18 hour readings and manual readings at 16-20 hours incubation. The WalkAway® SI had 9 results that were not readable at <16 hours for a no growth rate of 3%. Results were >95% reproducible for all read methods. Breakpoint readings were performed on the same 10 Enterococci isolates with reproducibility based on a category reading. Less than 16 hour readings resulted in ≥ 95% reproducibility with 3% no growth at <16 hour. Overnight readings performed on the same panels for the WalkAway® 16-18 hour readings and manual readings at 16-20 hours incubation were also ≥ 95% reproducible with no isolates that did not grow. b. Linearity/assay reportable range: Not Applicable c. Traceability, Stability, Expected values (controls, calibrators, or methods): The recommended Quality Control isolate was tested a sufficient number of times with acceptable results on all testing days with the reference method. All results grew in the 4.5-16 hour window. Quality control results demonstrated the ability of the different reading parameters (manual and {4} instrument) to produce acceptable results. The following table provides the frequency of the results in each concentration with the expected range stated. | Results | | | | | | | --- | --- | --- | --- | --- | --- | | Organism | Conc. in μg/mL | # reference | MicroScan® | | | | | | | Manual overnight | WalkAway® overnight | 4.5-15h WalkAway® SI | | E. faecalis ATCC 29212 Range 0.5-2 μg/mL | ≤ 0.12 | | | | | | | 0.25 | | | | | | | 0.5 | 31 | 3 | | | | | 1 | 53 | 80 | 84 | 84 | | | 2 | | 1 | | | | | 4 | | | | | The breakpoint panels using a separate reading algorithm also demonstrated acceptable quality control results with all at $\leq 2\ \mu\mathrm{g/mL}$. Inoculum density control: A turbidity meter was used for the turbidity inoculation method. d. Detection limit: Not Applicable e. Analytical specificity: Not Applicable f. Assay cut-off: Not Applicable 2. Comparison studies: a. Method comparison with predicate device: Clinical testing was conducted at 3 sites using fresh isolates supplemented with stock isolates. A total of 306 Enterococci spp. were tested of which 213 were fresh isolates. There were 75 challenge isolates tested at one site and compared to the reference broth dilution result mode that was determined by previous testing of each isolate multiple times in the recommended reference panel. The Synergies plus™ results were obtained at read times between 4.5 and 15 hours of incubation for >95% of the results. An additional comparison was done with readings on the instrument after overnight incubation and also read manually when incubated 16-18 hours. Performance by these alternate reading methods was also acceptable with no apparent differences or trends. {5} Comparison was made to the recommended CLSI reference method which was followed with the exception of the use of a small amount (0.1%) PLURONIC® in the final inoculum. A validation of the use of PLURONIC® in the frozen reference panels was conducted. Similar calculations for the different reading methods were performed with very little difference. The chart below demonstrates the performance of Synergies plus™ readings at <16 hours when compared to the reference method. | | total | EA | %EA | Total evaluable | EA of evaluable | %EA | CA | %CA | #R | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Clinical | 293 | 287 | 98.0% | 232 | 226 | 97.4% | 293 | 100% | 82 | 0 | 0 | | Challenge | 72 | 70 | 97.2% | 62 | 60 | 96.8 | 71 | 98.6% | 29 | 0 | 1 | | Combined | 365 | 357 | 97.8% | 294 | 286 | 97.3% | 364 | 99.7% | 111 | 0 | 1 | EA-Essential Agreement CA-Category Agreement R-resistant isolates maj-major discrepancies vmj-very major discrepancies Evaluable results are those that fall within the test range of the reference method and could also be on-scale with the new device if within the plus/minus one dilution variability. EA is when there is agreement between the reference method and the MicroScan® within plus or minus one serial two-fold dilution of antibiotic. CA is when the interpretation of the reference method agrees exactly with the interpretation of the MicroScan® result. Similar results were obtained when the algorithm for reading a breakpoint panel with 2, 4 and 8 µg/mL wells with no difference in CA. EA was not calculated for these readings since insufficient numbers of concentrations were available for the evaluation. b. Matrix comparison: Not Applicable 3. Clinical studies: a. Clinical Sensitivity: Not Applicable b. Clinical specificity: Not Applicable c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable {6} 4. Clinical cut-off: Not Applicable 5. Expected values/Reference range: Enterococcus spp. interpretive criteria: ≤ 8 (S) and ≥ 16 (R) All values are included in the package insert as is the quality control strain with recommended ranges. N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10. O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. 7 --- **Source:** [https://fda-staging.innolitics.com/device/K060088](https://fda-staging.innolitics.com/device/K060088) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com